title: Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters.
abstract: BACKGROUND
  Immunotherapy with monoclonal antibodies (MAbs) offers safe interventions for the prevention of infection in patients after organ transplantation and for the treatment of cancers and autoimmune diseases. MAb 201 is a severe acute respiratory syndrome-associated coronavirus (SARS-CoV)-specific MAb that prevents establishment of viral replication in vitro and prevents viral replication in vivo when administered prophylactically. The efficacy of MAb 201 in the treatment of SARS was evaluated in golden Syrian hamsters, an animal model that supports SARS-CoV replication to high levels and displays severe pathological changes associated with infection, including pneumonitis and pulmonary consolidation.
  
  
  METHODS
  Golden Syrian hamsters that were intranasally inoculated with SARS-CoV were treated with various doses of MAb 201 or an irrelevant MAb 24 h after inoculation. Two to 7 days after infection, the hamsters were killed, and their lungs were collected for evaluation of viral titers and pathological findings.
  
  
  RESULTS
  Postexposure treatment with MAb 201 can alleviate the viral burden and associated pathological findings in a golden Syrian hamster model of SARS-CoV infection. After a hamster is treated with MAb 201, its viral burden is reduced by 102.4-103.9 50% tissue-culture infectious doses per gram of tissue, and the severity of associated pathological findings, including interstitial pneumonitis and consolidation, is also remarkably reduced.
  
  
  CONCLUSIONS
  The demonstration of successful postexposure MAb 201 therapy in an animal model that demonstrates viral replication and associated pulmonary pathological findings suggests that MAb 201 may be useful in the arsenal of tools to combat SARS.
authors.affiliation: Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Anjeanette
authors.initials: A
authors.lastname: Roberts
authors.forename: William D
authors.initials: WD
authors.lastname: Thomas
authors.forename: Jeannette
authors.initials: J
authors.lastname: Guarner
authors.forename: Elaine W
authors.initials: EW
authors.lastname: Lamirande
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Babcock
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Greenough
authors.forename: Leatrice
authors.initials: L
authors.lastname: Vogel
authors.forename: Norman
authors.initials: N
authors.lastname: Hayes
authors.forename: John L
authors.initials: JL
authors.lastname: Sullivan
authors.forename: Sherif
authors.initials: S
authors.lastname: Zaki
authors.forename: Kanta
authors.initials: K
authors.lastname: Subbarao
authors.forename: Donna M
authors.initials: DM
authors.lastname: Ambrosino
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D006224:Cricetinae; D004195:Disease Models, Animal; D005260:Female; D007074:Immunoglobulin G / Q000097:blood; D007167:Immunotherapy; D008168:Lung / Q000473:pathology / Q000821:virology; D017563:Lung Diseases, Interstitial / Q000473:pathology; D008647:Mesocricetus; D009500:Neutralization Tests; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology* / Q000502:physiology; D045169:Severe Acute Respiratory Syndrome / Q000503:physiopathology / Q000628:therapy* / Q000821:virology; D019562:Viral Load
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D007074:Immunoglobulin G